摘要
本文对组蛋白去乙酰化酶(HDAC)抑制剂类上市药物进行了简要介绍,重点以具有我国自主知识产权并荣获第十九届中国专利金奖的药物西达本胺为研究对象,通过对其相关专利文献的检索、统计,对其申请量趋势、技术来源国区域分布、关键申请人、技术主题分布、法律状态等专利信息进行分析整理,并梳理了其技术演进脉络及发展路线。基于西达本胺上述专利信息提出些许建议,以期为中国医药企业的药物研发及专利布局等提供参考。
This paper provides a brief introduction of the marketed drugs of histone deacetylation(HDAC)inhibitors.Focusing on the Chinese independent intellectual drug chidamide as the research object,the patent information such as application volume trend,regional distribution of original country,key applicants,technical subject distribution,and legal status is analyzed and sorted by searching the relevant patent documents.The technological evolution and development route of the chidamide were also clarified.Based on the patent information above,some suggestions are made to provide reference for pharmaceutical development and distribution of patents for Chinese pharmaceutical company.
作者
迟丽娜
原悦
周付科
郭晓赟
王勤耕
CHI Li-na;YUAN Yue;ZHOU Fu-ke;GUO Xiao-yun;WANG Qin-geng(Patent Examination Cooperation(Beijing)Center of the Patent Office,CNIPA,Beijing 100081,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2020年第1期15-21,共7页
Chinese Journal of New Drugs
